Silence Therapeutics PLC
Company Profile
Business description
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Contact
72 Hammersmith Road
LondonW14 8TH
GBRT: +44 2034576900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
116
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,823.00 | 3.70 | -0.04% |
| CAC 40 | 7,902.25 | 23.79 | 0.30% |
| DAX 40 | 24,456.81 | 92.75 | -0.38% |
| Dow JONES (US) | 44,650.64 | 192.34 | 0.43% |
| FTSE 100 | 8,975.66 | 108.64 | 1.23% |
| HKSE | 24,380.04 | 351.67 | 1.46% |
| NASDAQ | 20,630.66 | 19.33 | 0.09% |
| Nikkei 225 | 39,593.84 | 52.52 | -0.13% |
| NZX 50 Index | 12,696.53 | 63.67 | -0.50% |
| S&P 500 | 6,280.46 | 17.20 | 0.27% |
| S&P/ASX 200 | 8,584.70 | 4.50 | -0.05% |
| SSE Composite Index | 3,538.80 | 29.12 | 0.83% |